Related Experiment Video
Updated: Jun 21, 2026
08:28
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
HER2+ breast cancer: how to evaluate?
1IPATIMUP, Institute of Molecular Pathology and Immunology and Medical Faculty, University of Porto, Porto, Portugal. fernando.schmitt@ipatimup.pt
Advances in Therapy
|August 12, 2009
Summary
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer impacts prognosis. Accurate HER2 testing is crucial for effective trastuzumab therapy, addressing issues like resistance and testing sensitivity.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- HER2 overexpression occurs in 15-30% of breast cancers, correlating with poorer prognosis without treatment.
- HER2 testing is standard, but variable sensitivity and specificity can affect treatment efficacy.
- Trastuzumab is a key therapy for HER2-positive breast cancer, but response can be variable.
Purpose of the Study:
- To review HER2-positive breast cancer characteristics.
- To explore the link between HER2 immunogenicity and response to HER2-targeted therapies, particularly trastuzumab.
- To identify challenges in HER2 assessment and therapeutic correlation.
Main Methods:
- Literature review focusing on HER2 biology, testing methodologies, and therapeutic outcomes.
- Analysis of factors influencing trastuzumab response in HER2-positive breast cancer.
- Discussion of diagnostic challenges and quality control in HER2 testing.
Main Results:
- Potential trastuzumab resistance mechanisms include phosphatase and tensin analog (PTEN) loss or altered receptor expression.
- Nonspecific or insensitive HER2 measurement methods can complicate therapeutic response assessment.
- Evaluating additional biomarkers alongside HER2 status may improve treatment stratification.
Conclusions:
- High-quality, validated HER2 testing is essential for optimal patient outcomes.
- Pathologists and oncologists must ensure accurate HER2 assessment for appropriate therapy selection.
- Addressing testing limitations and considering multifactorial patient assessment can enhance treatment efficacy in HER2+ breast cancer.
